The Rising Cost of Healthcare and Potential Impact of Biosimilars

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in full form in a peer-reviewed journal.

Psoriasis Prevalence is Increasing

Initial History of Monoclonal Antibody Development

Psoriasis: More Patients to Treat -- More Treatments for Patients -- More costs

Differences Between Biologics and Small Molecules

Challenges With Development of Biosimilar

What Could We Gain from Marketed Biosimilars?

Impact of the Biosimilar Filgrastim

The Therapeutic Relationship Between HCP and Patient is Important

Switching Patients From Originator to Biosimilar

Initiatives to Influence Uptake of Biosimilars

NOR-SWITCH Experience

Overview of Biosimilar Use Across Europe

UK HSCIC Data and Potential Savings From Just 1 Class of Drugs

UK HSCIC Data and Potential Savings From Just 1 Class of Drugs (cont)

Long-Term Data on Switching

Meta-Analyses on Switching From Reference Medicines to Biosimilars

Biosimilars and Extrapolation

National Clinical Audit of Biologic Therapies for IBD in the UK

Pharmacovigilance

Concluding Remarks

Abbreviations